Shanghai Haohai Biological Technology Co. Ltd
Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. It offers ophthalmology products consist of intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. The company also offers sodium hyaluronate injection, medical chitosan, medical sodium hyal… Read more
Market Cap & Net Worth: Shanghai Haohai Biological Technology Co. Ltd (5HB)
Shanghai Haohai Biological Technology Co. Ltd (F:5HB) has a market capitalization of $96.63 Million (€94.13 Million) as of March 19, 2026. Listed on the F stock exchange, this Germany-based company holds position #14198 globally and #1476 in its home market, demonstrating a 0.00% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Shanghai Haohai Biological Technology Co. Ltd's stock price €2.62 by its total outstanding shares 35929040 (35.93 Million).
Shanghai Haohai Biological Technology Co. Ltd Market Cap History: 2015 to 2026
Shanghai Haohai Biological Technology Co. Ltd's market capitalization history from 2015 to 2026. Data shows growth from $29.74 Million to $96.63 Million (13.24% CAGR).
Shanghai Haohai Biological Technology Co. Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Shanghai Haohai Biological Technology Co. Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.04x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.04 times its annual revenue
1740.90x
Lower than industry averageLatest Price to Earnings (P/E) Ratio
0.28x
Shanghai Haohai Biological Technology Co. Ltd's market cap is 0.28 times its annual earnings
0.11x
Higher than industry averageWhat These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $26.61 Million | $851.16 Million | $305.05 Million | 0.03x | 0.09x |
| 2017 | $26.86 Million | $1.34 Billion | $372.42 Million | 0.02x | 0.07x |
| 2018 | $31.58 Million | $1.55 Billion | $414.54 Million | 0.02x | 0.08x |
| 2019 | $43.14 Million | $1.60 Billion | $370.78 Million | 0.03x | 0.12x |
| 2020 | $49.39 Million | $1.32 Billion | $230.07 Million | 0.04x | 0.21x |
| 2021 | $61.10 Million | $1.75 Billion | $352.23 Million | 0.03x | 0.17x |
| 2022 | $59.58 Million | $2.10 Billion | $180.47 Million | 0.03x | 0.33x |
| 2023 | $70.86 Million | $2.63 Billion | $416.12 Million | 0.03x | 0.17x |
| 2024 | $119.49 Million | $2.68 Billion | $420.45 Million | 0.04x | 0.28x |
Competitor Companies of 5HB by Market Capitalization
Companies near Shanghai Haohai Biological Technology Co. Ltd in the global market cap rankings as of March 19, 2026.
Key companies related to Shanghai Haohai Biological Technology Co. Ltd by market ranking:
- Vertex Pharmaceuticals Inc (NASDAQ:VRTX): Ranked #165 globally with a market cap of $114.33 Billion USD.
- Regeneron Pharmaceuticals Inc (NASDAQ:REGN): Ranked #285 globally with a market cap of $73.32 Billion USD.
- CSL Limited (PINK:CMXHF): Ranked #340 globally with a market cap of $63.46 Billion USD.
- argenx SE (OTCGREY:ARGNF): Ranked #497 globally with a market cap of $42.99 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #165 | Vertex Pharmaceuticals Inc | NASDAQ:VRTX | $114.33 Billion | $451.59 |
| #285 | Regeneron Pharmaceuticals Inc | NASDAQ:REGN | $73.32 Billion | $744.12 |
| #340 | CSL Limited | PINK:CMXHF | $63.46 Billion | $149.87 |
| #497 | argenx SE | OTCGREY:ARGNF | $42.99 Billion | $697.42 |
Shanghai Haohai Biological Technology Co. Ltd Historical Marketcap From 2015 to 2026
Between 2015 and today, Shanghai Haohai Biological Technology Co. Ltd's market cap moved from $29.74 Million to $ 96.63 Million, with a yearly change of 13.24%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | €96.63 Million | 0.00% |
| 2025 | €96.63 Million | -19.14% |
| 2024 | €119.49 Million | +68.63% |
| 2023 | €70.86 Million | +18.94% |
| 2022 | €59.58 Million | -2.49% |
| 2021 | €61.10 Million | +23.72% |
| 2020 | €49.39 Million | +14.49% |
| 2019 | €43.14 Million | +36.58% |
| 2018 | €31.58 Million | +17.59% |
| 2017 | €26.86 Million | +0.93% |
| 2016 | €26.61 Million | -10.53% |
| 2015 | €29.74 Million | -- |
End of Day Market Cap According to Different Sources
On Mar 19th, 2026 the market cap of Shanghai Haohai Biological Technology Co. Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $96.63 Million USD |
| MoneyControl | $96.63 Million USD |
| MarketWatch | $96.63 Million USD |
| marketcap.company | $96.63 Million USD |
| Reuters | $96.63 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.